Upregulation of RASAL2 promotes proliferation and metastasis, and is targeted by miR-203 in hepatocellular carcinoma

Introduction

Hepatocellular carcinoma (HCC) is reported to be the fifth most common cancer type and the second leading cause of cancer-associated mortality worldwide (1,2). Risk factors are well characterized and surgical resections well developed; however, the long-term survival rate of patients with HCC is poor. The five-year survival rate following resection is limited to 30–40% (3). It is therefore of primary concern to clarify the molecular pathogenesis of HCC and develop novel effective treatment strategies.

RAS protein activator like 2 (RASAL2) is a protein that contains a GTPase activating protein (GAP)-related domain, which is characteristic of GAP proteins. A previous study demonstrated that RASAL2 acts as an epithelial cell transforming-2-interacting protein to mediate mesenchymal-amoeboid transition by regulating rhodopsin activity (4). In addition, Feng et al (5) reported that RASAL2 promotes triple-negative breast cancer (TNBC) progression by activating Ras-related C3 botulinum toxin substrate 1 (RAC1). RASAL2 binds to and antagonizes RAC1-GAP protein ARHGAP24 to suppress breast cancer invasion. Furthermore, RASAL2 has been reported to be hypomethylated in HCC (6); however, the potential role of RASAL2 in HCC remains to be elucidated.

The present study aimed to research the expression pattern and functional role of RASAL2 in HCC. The present study demonstrated that RASAL2 was markedly upregulated in HCC tissues. Functional assays in HuH-7 and HCC-LM3 cells demonstrated that RASAL2 promoted proliferation and invasion in HCC. In addition, results indicated that RASAL2 was a direct target of microRNA (miRNA/miR)-203 in HCC. The data therefore suggested that RASAL2 is important in HCC progression.

Materials and methods

Patients and tissue samples

The present study included 70 patients underwent resection of HCC at the First Affiliated Hospital of Zhejiang University School of Medicine (Hangzhou, China). The tumor and non-tumor tissues were maintained in liquid nitrogen immediately following resection. The inclusion criteria required were as follows: i) Diagnosis of HCC confirmed by pathology; ii) without anticancer treatment and distant metastases before surgery; iii) underwent curative resection for HCC between 2010 and 2015, defined as macroscopically complete removal of the tumor with negative safety margin; and iv) with complete clinicopathologic and follow-up data. The characteristics of patients are presented in Table I. This study was approved by the Ethical Review Committee of the First Affiliated Hospital of Zhejiang University School of Medicine (Hangzhou, China) and informed consent was obtained from all patients.

Table I. Correlations between RASAL2 levels and clinicopathological characteristics in hepatocellular carcinoma patients.

Table I.

Correlations between RASAL2 levels and clinicopathological characteristics in hepatocellular carcinoma patients.

		RASAL2 levels
Characteristic	Patients (n=70)	Positive	Negative	P-value
Age (years)				1.000
≤50	28	18	10
>50	42	27	15
Gender				0.828
Male	55	35	20
Female	15	10	5
Tumor number				0.098
Single	30	16	14
Multiple	40	29	11
Tumor size (cm)				0.015a
≤5	26	12	14
>5	44	33	11
Tumor node metastasis stage				0.212
I,II	35	20	15
III	35	25	10
Grade				0.785
Well, moderate	49	31	18
Poor	21	14	7
α-fetoprotein (ng/ml)				0.174
≤400	21	11	10
>400	49	34	15
Portal vein invasion				0.237
Negative	50	30	20
Positive	20	15	5

{ label (or @symbol) needed for fn[@id='tfn1-mmr-15-05-2720'] } χ² tests were used to analyze the correlation.

a P<0.05 was considered to indicate a statistically significant difference. RASAL2, RAS protein activator like 2.

Cell lines and culture

HuH-7 and HCC-LM3 liver cancer cell lines were purchased from the Shanghai Institute of Cell Biology (Shanghai, China). These two cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco, Thermo Fisher Scientific, Inc.) at 37°C in an atmosphere containing 5% CO2.

RNA oligoribonucleotides and transfection

Small interfering RNA (si)-RASAL2 (SI04200945), AllStars negative control (NC) siRNA (SI03650318) and miR-203 (MSY0000264) were purchased from Qiagen GmbH (Hilden, Germany). The transfection was performed using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol once cells reached 30–50% confluence.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting

Total RNA from the HCC cell lines was isolated using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) in accordance with the manufacturer's protocol. Subsequently, cDNA was synthesized and qPCR reactions were performed using the ABI7500 Fast system (Applied Biosystems; Thermo Fisher Scientific, Inc.). Briefly, reverse transcription was performed as follows the total 20 µl reaction compound consisted of 10 µl 2xmiRNA Reaction Buffer mix, 0.1% 2 µl BSA, 2 µl miRNA PrimeScript RT Enzyme Mix, 1 µl RNA and 5 µl RNase Free dH2O. All regents used were purchased from Takara Biotechnology Co., Ltd. (Dalian, China). Next, the reaction compound was then incubated at 37°C for 1 h and then 85°C for 5 min. Subsequently 80 ul RNase Free dH2O was added to the compound and it was stored at −80°C until use. qPCR was performed using a total 20 µl reaction volume consisting of 2 µl SYBR Premix Ex TaqTM II (2x), 0.8 µl PCR Forward Primer (10 µM), 0.8 µl Uni-miR qPCR Primer (10 µM), 0.4 µl ROX Reference Dye II (50x), 2 µl synthesized cDNA and 6 µl dH2O. All the regents used were purchased from Takara Biotechnology Co., Ltd. The thermocycling conditions were as follows: 40 cycles of denaturation for 15 sec at 95°C and extension for 60 sec at 60°C. GAPDH and U6 served as internal controls. The results were quantified by 2−∆∆Cq method (7). The sequences of primers used in the present study were as follows: RASAL2, forward CCA AAT GTC AGT GGA AGC CTC TC, reverse CTG TGT TGT CCT GGC TTG GAG A; and GAPDH, forward GTC TCC TCT GAC TTC AAC AGC G and reverse, ACC ACC CTG TTG CTG TAG CCA A. The primers for miR-203 (MS00003766) and U6 (MS00033740) were obtained from Qiagen GmbH.

For western blotting, cells were lysed in radioimmunoprecipitation buffer (Beyotime Institute of Biotechnology, Haimen, China) accompanied by phenylmethane sulfonyl fluoride (Beyotime Institute of Biotechnology). The concentration of each protein was quantified by Pierce BCA Protein Assay kit (23225, Thermo Fisher Scientific, Inc.). For each sample, 30 µg protein was separated by 10% SDS-PAGE. The proteins were then transferred to polyvinylidene membranes, which were blocked with 5% non-fat milk at room temperature for 1 h. The washing regent used for the western blotting analysis was PBST. The primary antibodies used in the study were as follows: RASAL2 (1:300; ab121578; Abcam, Cambridge, MA, USA), phosphorylated-AKT (p-AKT; 1:3,000; ab81283; Abcam, Cambridge, MA, USA), β-actin (1:4,000; A5441; Sigma-Aldrich; Merck Millipore, Darmstadt, Germany), Anti-rabbit IgG, horseradish peroxidase (HRP)-conjugated antibody (7074, Cell Signaling Technology) and anti-mouse IgG, HRP-conjugated antibody (7076, Cell Signaling Technology). An enhanced chemiluminescence kit (NCI4106, Huiying Biotec, Shanghai, China) was used to visualize the membranes.

Immunohistochemistry (IHC)

Immunostaining was performed on paraffin-embedded specimens as previously described (8). The antibody used for IHC was RASAL2 (1:400; ab121578; Abcam, Cambridge, MA, USA). For evaluation of the staining score, semi-quantitative estimation was applied as previously described (9). Intensity was graded as 0, no staining; i) weak staining; ii) moderate staining; or iii) strong staining. The abundance of positive cells was graded from 0 to 4 (0, <5% positive cells; i) 5–25% positive cells; ii) 26–50% positive cells; iii) 51–75% positive cells; iv) >75% positive cells). The final score was obtained by multiplying the two values and all the cases were grouped as RASAL2-negative (scores between 1 and 6) and RASAL2-positive (scores between 7 and 12).

Cell proliferation and transwell assay

The proliferation of the HuH-7 and HCC-LM3 cells was evaluated using the Cell Counting Kit (CCK)-8 (Dojindo Molecular Technologies, Inc., Kumamoto, Japan). The transfected cells were plated into 96-well plates at a density of 5×103 cells/well. Following incubation with the CCK reagent for 2 h, the optical density of each well was measured with a Thermomax microplate reader (Sunnyvale, CA, USA) at a wavelength of 450 nm. The assays were conducted at three different time points (24, 48 and 72 h) and the experiments were conducted in triplicate.

For the transwell assay, 5×104 transfected cells in serum-free DMEM were seeded into the upper chambers of inserts (Corning Incorporated-Life Sciences, Tewkesbury, MA, USA), which were coated with Matrigel (BD Biosciences, San Jose, CA, USA). DMEM supplemented with 10% fetal bovine serum was added to the lower chambers. Following incubation for 48 h, the lower surface was stained with crystal violet. The cells were then counted under an inverted microscope with ×100 magnification.

Luciferase activity assay

A luciferase reporter assay was conducted using the Dual-Luciferase Reporter Assay system (E2920; Promega Corporation, Madison, WI, USA) according to the manufacturer's protocol. HuH-7 cells were seeded in 24-well plates and were co-transfected with miR-203 mimics or NC, and wild-type or mutant-type RASAL2 3′untranslated region (UTR) plasmid, which was synthesized and mutated by Genechem Co., Ltd. (Shanghai, China). All the binding sites were mutated. The firefly and Renilla luciferase activities were measured by a dual-luciferase reporter assay (Promega Corporation) following transfection for 48 h.

Statistical analysis

The correlations between RASAL2 levels and clinicopathological data were analyzed using a χ2 test. The comparisons between groups were analyzed using paired Student's t-test. The data is presented as the mean ± standard deviation. Statistical analyses were performed with SPSS software version 17.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5 (Graphpad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

RASAL2 is upregulated in HCC tissues

In order to explore the expression pattern of RASAL2 in HCC, the present study performed IHC on 70 pairs of HCC tissues. As presented in Fig. 1, the immunoreactivity of RASAL2 was primarily located in the cytoplasm. The results indicated that the levels of RASAL2 were markedly increased in HCC compared with in normal liver tissues. Of all the tissues, 45 of 70 (64.3%) HCC tissues were positive for RASAL2, whereas only 15 of 70 (21.4%) normal liver tissues were positive.

Figure 1. Protein expression of RAS protein activator like 2 was detected by immunohistochemistry. Representative images of tumor and non-tumor tissues were captured at the magnification of ×400.

Subsequently, the present study investigated whether the levels of RASAL2 were correlated with clinicopathological parameters in these 70 HCC tissues by applying χ2 test (Table I). The results revealed that the positive RASAL2 expression group exhibited a larger tumor size (P=0.015). However, no further correlations between RASAL2 levels and other clinicopathological characteristics were observed, including, gender, age, tumor number, grade and α-fetoprotein.

RASAL2 knockdown inhibits cell proliferation and metastasis in HCC cells

Chemically synthesized siRNA was used to knockdown RASAL2 in HuH-7 and HCC-LM3 cells. RT-qPCR was applied to detect the knockdown efficiency of si-RASAL2 (Fig. 2A). In order to evaluate the proliferation rate, a CCK-8 assay was conducted. The results revealed that the growth rate decreased following inhibition of RASAL2 in Huh7 and HCC-LM3 cells (Fig. 2B). To further determine the significance of RASAL2 in HCC, a transwell assay was applied to investigate the effects of RASAL2 on HCC cell invasion. It was observed that RASAL2 knockdown markedly reduced the invasion of HCC cells (Fig. 2C). The phosphoinositide 3 kinase (PI3K)/AKT pathway has been reported to be important in HCC proliferation and metastasis (10,11). The present study hypothesized that RASAL2 may regulate the PI3K/AKT pathway in HCC cells. To verify this, the present study investigated p-AKT levels, since p-AKT is the key protein of the AKT pathway. It was observed that RASAL2 suppression markedly reduced the expression levels of p-AKT compared with the control group in the two cell lines (Fig. 2D). These results indicated that RASAL2 promotes proliferation and invasion in HCC.

Figure 2. RASAL2 inhibition suppressed cell proliferation and metastasis in HCC cells. (A) Inhibition efficiency of RASAL2 was confirmed by reverse transcription-quantitative polymerase chain reaction. (B) Cell Counting Kit-8 was applied to determine the proliferation rate of HCC cells at three different time points (24, 48 and 72 h). (C) Transwell assay was used to examine the invasive ability of HCC cells. Magnification, ×200. (D) Western blotting was used to detect the protein levels of p-AKT following RASAL2 suppression. Representative images are presented. *P<0.05 and **P<0.01 were considered significant. RASAL2, RAS protein activator like 2; HCC, hepatocellular carcinoma; p-AKT, phosphorylated-AKT; si, small interfering RNA; NC, negative control; OD, optical density.

RASAL2 is a direct target of miR-203 in HCC

miRNAs have recently been demonstrated to act as critical molecules that regulate proliferation and metastatic progression by binding target genes in HCC (12–14). The present study hypothesized that RASAL2 may be targeted by a specific miRNA in HCC. Following application of TargetScan (http://www.targetscan.org) and miRanda (http://www.microrna.org) computational tools, miR-203 was investigated (Fig. 3A). This specific miRNA was identified by the two bioinformatics tools. Previous studies have reported that miR-203 is downregulated in HCC, and inhibits proliferation and metastasis in HCC (15,16). The miR-203 mimics were used to enhance the level of miR-203 in HCC cells (Fig. 3A). A dual-luciferase reporter assay was conducted in HuH-7 cells and the results revealed that miR-203 mimics significantly inhibited the luciferase activity of wild-type RASAL2 3′UTR rather than the mutant type (Fig. 3B). In addition, western blotting indicated that the protein levels of RASAL2 were decreased following miR-203 overexpression (Fig. 3B). Furthermore, similar to si-RASAL2, miR-203 mimics exerted anti-proliferative and anti-metastatic effects in HCC cells (Fig. 3C and D). These data suggested that RASAL2 may be a direct target of miR-203 in HCC.

Figure 3. RASAL2 was a direct target of miR-203 in HCC. (A) TargetScan and miRanda predicted the binding sequences of miR-203 and RASAL2, and the complementary sites were mutated. (B) miR-203 mimics reduced the luciferase activity of wt RASAL2 3′untranslated region and protein levels of RASAL2. (C) Cell Counting Kit-8 and (D) Transwell assay indicated that miR-203 mimics inhibited proliferation and metastasis of HCC cells. RASAL2, RAS protein activator like 2; HCC, hepatocellular carcinoma; NC, negative control; wt, wild-type; mt, mutant; miR, microRNA; OD, optical density. *P<0.05, **P<0.01.

Discussion

HCC is one of the leading causes of malignancy-associated mortality in humans worldwide. The development of surgical resection, drug targets and other therapeutic strategies is well established; however, the prognosis of HCC remains poor. The identification of molecular markers in HCC has been the primary target of research (17–19); therefore, the present study aimed to identify a novel therapeutic biomarker for HCC.

The present study demonstrated that the expression levels of RASAL2 were markedly overexpressed in HCC tissues compared with in normal liver tissues. In a previous study, Stefanska et al (6) reported that the promoters of RASAL2 are hypomethylated, which results in the increased expression of RASAL2 in HCC tissues and cell lines. The data from the present study suggested that RASAL2 acts as an oncogene in HCC development. In addition, the correlation between RASAL2 and clinicopathological features in HCC was investigated, and it was observed that high RASAL2 expression was closely correlated with tumor size. Subsequently, RASAL2 expression was suppressed in HuH-7 and HCC-LM3 cells based on the observations from the HCC tissues, in order to elucidate its functional role in HCC. The results demonstrated that knockdown of RASAL2 decreased the growth rate and metastatic ability of HCC cells. It has previously been reported that RASAL2 functions as a tumor oncogene in TNBC (5), and this is consistent with the results of the present study. The overexpression of RASAL2 in TNBC drives mesenchymal invasion and is correlated with poor outcomes. This further confirms the oncogenic role of RASAL2 in human cancer.

The present study aimed to identify pathways mediating proliferation and metastasis in HCC. The PI3K/AKT pathway, which regulates growth and invasion during cancer development, including HCC, was studied (20,21). Following suppression of RASAL2, the phosphorylation levels of AKT were reduced in the two HCC cell lines. This result suggested that the over-expression of RASAL2 in HCC may activate the AKT pathway resulting in increases in proliferation and invasion.

miRNAs are small non-coding RNAs that regulate gene expression by inhibiting translation and/or stability of mRNA, and thereby contribute to a wide range of physiological and pathological processes (22–24). In human cancer, numerous miRNAs act as potential tumor suppressor genes and low levels of these miRNAs may contribute to overexpression of oncogenic genes (25,26). RASAL2 was revealed to serve an oncogene role in HCC; therefore, the present study hypothesized that high levels of RASAL2 may be attributed to the downregulation of a specific miRNA. miR-203 has been reported to be frequently downregulated in various cancer types, including HCC (27–29). A previous study revealed that RASAL2 is a direct target of miR-203 in breast cancer. The present study, to the best of our knowledge, is the first to confirm that miR-203 directly targets RASAL2 in HCC, according to the following evidence: i) Dual-luciferase reporter assay revealed a decrease in luciferase activity in cells co-transfected with miR-203 mimics and wild-type RASAL2 3′UTR, whereas no change was observed in cells transfected with the mutant RASAL2 3′UTR; ii) the protein levels of RASAL2 were decreased following transfection with miR-203 mimics; iii) the effects of miR-203 mimics on proliferation and metastasis were similar to those exhibited following inhibition of RASAL2. These data therefore suggested that miR-203 may directly target RASAL2 in HCC.

In conclusion, the results of the present study indicated that RASAL2 is significantly upregulated in HCC tissues. In addition, it was confirmed that RASAL2 promotes proliferation and metastasis by regulating the AKT pathway. Furthermore, it was demonstrated that RASAL2 is the direct target of the tumor suppressor gene miR-203. These data are expected to contribute to mechanistic HCC development and RASAL2 may be considered a potential novel molecular target for the development of future therapeutic technologies.

References